MOR - Margin resik MorphoSys AG

MorphoSys Corp - logo grafis emiten MOR

MorphoSys AG (MOR) minimizes risks by developing targeted antibodies in partnership with pharmaceutical behemoths. Average sales margins show a pivot driven by strict FDA oversight and exclusive patents for oncology drugs. Stable demand for innovation renders the asset defensive, isolating it from macroeconomic volatility. The value of -226.90 is established as the baseline value determining the company's current operational efficiency.

Margin dodolan perusahaan morphosys.com (MOR): kanggo periode 04.07.2022 - 10.08.2024

Ringkesan rincian data analitis MorphoSys AG (MOR)

- rega saham lan prakiraan rega para ahli:
Ringkesan analitik perusahaan:morphosys.com - MOR
Produk asil prodhuksi MorphoSys Corporation

This indicator calculates the ratio of net income to revenue, determining the efficiency of cost management. It demonstrates the portion of income remaining after all operating and tax payments. For MorphoSys AG (MOR), this metric stabilizes due to royalties and the diversification of its antibody portfolio. Analyzing the net profit margin allows for the identification of abnormal peaks, which helps investors avoid overpaying for the asset.

Analisis pesaing

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Personalis Inc PSNL|Erasca Oncology - Margin dodolan resik|Tingkat bathi resik DCTH (Delcath Corp)|YMAB: Margin dodolan resik|AURA - Margin dodolan perusahaan|CADL (Candel Therapeutics Inc.) - Margin dodolan resik|Rentabilitas dodolan resik ARAY (Accuray)|Rentabilitas dodolan miturut bathi resik SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Margin resik|Margin resik Citius Oncology, Inc. CTOR|HURA - Rentabilitas dodolan miturut bathi resik|protaratx.com - Margin dodolan resik|FATE - Margin dodolan resik|WHWK: Margin dodolan resik|TScan Therapeutics (TCRX) - Margin dodolan resik|Margin resik Champions Oncology|Margin resik XBIT|Margin dodolan resik CVM|Rentabilitas dodolan miturut bathi resik OS Therapies Inc. OSTX|Margin resik Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Margin resik|ANL - Margin resik|Margin resik verupharma.com|TPST: Margin dodolan resik|XLO - Margin dodolan perusahaan|Margin resik Renovaro|Margin dodolan resik muraloncology.com|Margin dodolan resik KAPA|Margin dodolan perusahaan OnKure Therapeutics, Inc.|Margin dodolan resik GDTC (w2.cytomed.sg)|CRIS - Rentabilitas dodolan miturut bathi resik|Apollomics - Margin dodolan resik|Tharimmune Corp (THAR) - Rentabilitas dodolan miturut bathi resik|ADVB: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Margin dodolan resik|Rentabilitas dodolan resik SBFM (Sunshine Biopharma)|Margin resik Xenetic Bio (XBIO)|Margin resik SLRX (Salarius Pharma)|Kitov Pharma - Rentabilitas dodolan miturut bathi resik|American Oncology Network (AONC) - Margin resik|BeiGene - Margin dodolan resik|Checkpoint Therapeutics, Inc. (CKPT) - Rentabilitas dodolan miturut bathi resik|ELEV (Elevation Oncology, Inc.) - Rentabilitas dodolan miturut bathi resik|iCAD Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik IKNA|Margin dodolan resik notablelabs.com|Rentabilitas dodolan miturut bathi resik VIRX (Viracta Therapeutics Inc.)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)